Sera Prognostics develops simple blood tests that predict preterm birth, preeclampsia and other pregnancy complications. Using these tests, physicians can make early and accurate assessment of pregnancy complication risks so they can effectively manage their patients’ pregnancies.
ReVision Optics develops custom optical solutions dedicated to vision correction. Its first product is the Vue+ inlay, a unique patented refractive surgery solution which improves near vision that has been lost by presbyopia, the eye's natural aging process. Vue+ is approved in Europe, has its CE mark, and ReVision is actively pursuing regulatory approvals and market opportunities worldwide.
RadioRx discovers and develops compounds sourced and adapted from the aerospace industry for treating cancer and other indications.
QuatRx Pharmaceuticals is focused on discovering, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic areas.
On Demand Therapeutics (ODTx) is developing implantable devices to enable on-demand release of drugs to the back of the eye, controlled by the ophthalmologist, leveraging existing equipment and skills. In addition to its own intellectual property, ODTx has acquired rights to the patent portfolio and technical expertise developed by InterWest company MicroCHIPS in the areas of implantable drug delivery and monitoring devices.
Ocera Therapeutics, founded in January 2005, is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for gastrointestinal and liver diseases.
NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders by responsive brain stimulation. The company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide. In addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world. NeuroPace is located in Mountain View, California.
Neuronetics is a medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. It is the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment.
Nanostim is developing a self-contained leadless cardiac pacemaker system to eliminate the leads and surgical pocket required by conventional pacemakers, thereby removing the associated complications of infection and mechanical lead failure. The Nanostim approach changes pacemaker therapy delivery from a surgical procedure to a less-invasive, simplified catheter-based procedure.
Microfabrica is a developer of micro- and millimeter-scale devices and systems. Its breakthrough process and materials enable the development of Ultra-High Precision™ Parts, SubAssemblies and 3D MicroMachines, which are used in a variety of medical-device, semiconductor-test and aerospace applications.